Clinical Trial

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-11.
Trial Details
NCT Number NCT06255223
Lead Sponsor Jinling Hospital, China
Conditions Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
Enrollment 35 participants
Start Date 2023-12-15
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-03